Wei Lin

Wei Lin

Auto-generated profile, based on publicly available information

Wei Lin

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
XHXueling Hu
Xueling Hu
CSChanjuan Shen
Chanjuan Shen
TMTing Meng
Ting Meng
JOJoshua D. Ooi
Joshua D. Ooi
PEPeter James Eggenhuizen
Peter James Eggenhuizen
YZYong Zhong
Yong Zhong
Background: Several lines of evidence implicate that there are distinct differences between patients with myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane (GBM) antibody double-seropositive patients (DPPs) and single-positive patients. Hence, we conducted a retrospective study from a single center in China to analyze the clinical and pathological features, and prognosis of DPPs.Methods: 109 patients with MPO-ANCA-associated vasculitis (MPO-AAV), 20 DPPs and 23 patients diagnosed with anti-GBM disease from a large center in China were included in this study. The ratio of patients with renal biopsy in three groups were 100%, 50% and 100%, respectively. Their clinical and pathological characteristics, and outcomes were analyzed. The intensity of immune deposits in the kidney at diagnosis was detected by immunofluorescence (IF). Furthermore, multivariate Cox hazard model analysis was used to assess the clinical and histological predictors of end-stage renal disease (ESRD) and death for DPPs.Results: In our study, we found that patients in the DPPs group were older than the other two groups (p = 0.007, MPO-AAV vs. DPPs; p < 0.001, DPPs vs. anti-GBM). The DPPs group had a higher value of serum creatinine (p = 0.041) and lower estimated glomerular filtration rate (eGFR) (p = 0.032) compared with MPO-AAV patients. On the contrary, the DPPs group had a lower serum creatinine (p = 0.003) compared with patients with anti-GBM group. The proportion of patients with cardiac system involvement in the DPPs group was higher than anti-GBM patients (p = 0.014). Cellular crescents could be generally observed in renal biopsy of DPPs and patients with anti-GBM glomerulonephritis. In addition, Bowman’s capsule rupture was more common in DPPs than MPO-AAV patients (p = 0.001). MPO-AAV had a better renal and overall survival outcome than DPPs (p < 0.001). There was no significant difference of renal and overall survival outcome between DPPs and patients with anti-GBM disease. The incidence of ESRD in DPPs was negatively associated with lymphocyte count (HR 0.153, 95% CI 0.027 to 0.872, p = 0.034) and eGFR (HR 0.847, 95% CI 0.726 to 0.989, p = 0.036). Elevated serum creatinine was confirmed as a risk factor of both renal (HR 1.003, 95% CI 1.000 to 1.005, p = 0.019) and patient survival in DPPs (HR1.461, 95% CI 1.050 to 2.033, p = 0.024).Conclusion: In summary, compared with anti-GBM disease, DPPs tended to involve multi-organ damage rather than limited to the kidney. It is highlighted that serologic DPPs have a worse renal and patient prognosis than MPO-AAV. Moreover, we found that the risk factors of renal survival of DPPs include low lymphocyte count, elevated serum creatinine and reduced eGFR, and serum creatinine can predict patient survival.

26 March 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
TWTing Wu
Ting Wu
CSChanjuan Shen
Chanjuan Shen
YZYong Zhong
Yong Zhong
JOJoshua D. Ooi
Joshua D. Ooi
YZYa-Ou Zhou
Ya-Ou Zhou
PXPing Xiao
Ping Xiao
In antineutrophil cytoplasmic autoantibody (ANCA)‑associated vasculitides (AAV), the two major target antigens of ANCA are proteinase 3 (PR3) and myeloperoxidase (MPO). Evidence is accumulating that there are distinct differences between patients with PR3‑AAV and those with MPO‑AAV. In the present study, the clinicopathological features and prognosis of patients with PR3‑AAV and MPO‑AAV from a single center in China were retrospectively analyzed. A total of 212 Chinese patients with AAV were recruited in the present study; 189/212 (89.15%) patients were classified as having MPO‑AAV and 23/212 (10.85%) patients as having PR3‑AAV. Compared with those in the PR3‑AAV group, patients in the MPO‑AAV group were older and less frequently had ear, nose and throat or ophthalmic involvement. MPO‑AAV patients had higher levels of serum creatinine and proteinuria at baseline. No significant difference was observed with regard to the pathological changes of the glomeruli and tubulointerstitium between the two groups. The probability of developing end‑stage renal disease was significantly higher in patients with MPO‑AAV compared with that in patients with PR3‑AAV. There was no significant difference in the one‑year patient survival rate between the two groups. However, differences in certain clinical characteristics and outcomes were observed between MPO‑AAV and PR3‑AAV patients. A large national investigation of AAV is required to confirm the concept that PR3‑AAV and MPO‑AAV are distinct disease entities.

22 September 2021 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
TMTing Meng
Ting Meng
CSChanjuan Shen
Chanjuan Shen
RTRong Tang
Rong Tang
WLWei Lin
Wei Lin
JOJoshua D. Ooi
Joshua D. Ooi
XXXiangcheng Xiao
Xiangcheng Xiao

12 March 2026 in JACC: Advances
Verified
Journal Article
Open access
WLWei Lin
Wei Lin
ASAdam Schweber
Adam Schweber
YXYunwen Xu
Yunwen Xu
ACAlexander R. Chang
Alexander R. Chang
YFYoussef Mk. Farag
Youssef Mk. Farag
JSJung-Im Shin
Jung-Im Shin

15 January 2026 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
WLWei Lin
Wei Lin
ACAlexander R. Chang
Alexander R. Chang
DCDeidra C. Crews
Deidra C. Crews
TPTanjala S. Purnell
Tanjala S. Purnell
LALawrence J. Appel
Lawrence J. Appel
MUMark L. Unruh
Mark L. Unruh

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
LMLeenus Martin
Leenus Martin
ELErin D. Lew
Erin D. Lew
RPRoopal Patel
Roopal Patel
JOJoanne Oh
Joanne Oh
JZJingchuan Zhang
Jingchuan Zhang
RSRobert Shoemaker
Robert Shoemaker
KRAS mutations occur in about 25% of all cancers and promote oncogenesis via constitutive activation of the RAS/MAPK pathway. Targeting KRAS mutant tumors by inhibiting individual nodes in the RAS/MAPK pathway, including SHP2, SOS1, KRAS, RAF, MEK, and ERK, has shown early clinical activity, but the rapid emergence of resistance limits the benefit of monotherapy. Resistance is often mediated by reactivation of RAS/MAPK pathway signaling, which can occur by increased activation of upstream of the RAS/MAPK pathway (e.g., EGFR activation) and/or activation of RAS/MAPK pathway nodes (e.g., oncogenic BRAF and MEK mutations). Inhibiting both upstream and downstream RAS/MAPK pathway nodes has the potential to more robustly prevent reactivation relative to inhibition of a single node alone. We are currently exploring the combination of an inhibitor of an upstream node, SHP2, with ERAS-601 and the terminal downstream node, ERK1/2, with ERAS-007 (our first “MAPKlamp”) in nonclinical models. We evaluated this MAPKlamp in NSCLC, CRC, and pancreatic tumor models that harbored KRAS mutations in vitro and in vivo. In 14-day clonogenic assays in KRAS mutant NSCLC, CRC, and PDAC cell lines, this MAPKlamp inhibited colony growth more potently than ERAS-601 or ERAS-007 alone. In KRAS mutant CDX and PDX models, this MAPKlamp’s in vitro activity was observed in vivo where it achieved superior tumor growth inhibition and tumor regression relative to ERAS-601 and ERAS-007 monotherapy. This MAPKlamp showed in vitro and in vivo combination activity in KRAS mutant tumors, and these results support its clinical evaluation in RAS/MAPK pathway-driven tumors. Citation Format: Leenus Martin, Erin D. Lew, Roopal Patel, Joanne Oh, Jingchuan Zhang, Robin Nevarez, Taylor Congdon, Wei Lin, Les Brail, Robert Shoemaker. ERAS-007 (ERK inhibitor) + ERAS-601 (SHP2 inhibitor) exhibit nonclinical combination activity across KRAS mutated NSCLC, CRC, and PDAC tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2669.